Share-based Payment Arrangement, Expense of Denali Therapeutics Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Denali Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $25,135,000, a 1.1% increase year-over-year.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $100,760,000, a 2.9% decline year-over-year.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $102,878,000, a 4.8% decline from 2023.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $108,102,000, a 8.3% increase from 2022.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $99,847,000, a 17% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Denali Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $100,760,000 $25,135,000 +$275,000 +1.1% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $100,485,000 $25,387,000 +$287,000 +1.1% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $100,198,000 $25,160,000 -$2,680,000 -9.6% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $102,878,000 $25,078,000 -$911,000 -3.5% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $103,789,000 $24,860,000 -$2,599,000 -9.5% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $106,388,000 $25,100,000 -$1,470,000 -5.5% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $107,858,000 $27,840,000 -$244,000 -0.87% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $108,102,000 $25,989,000 +$802,000 +3.2% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $107,300,000 $27,459,000 +$2,880,000 +12% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $104,420,000 $26,570,000 +$2,634,000 +11% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $101,786,000 $28,084,000 +$1,939,000 +7.4% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $99,847,000 $25,187,000 +$3,102,000 +14% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $96,745,000 $24,579,000 +$3,581,000 +17% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $93,164,000 $23,936,000 +$2,800,000 +13% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $90,364,000 $26,145,000 +$5,117,000 +24% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $85,247,000 $22,085,000 +$8,255,000 +60% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $76,992,000 $20,998,000 +$7,746,000 +58% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $69,246,000 $21,136,000 +$8,652,000 +69% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $60,594,000 $21,028,000 +$10,243,000 +95% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $50,351,000 $13,830,000 +$4,941,000 +56% 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
Q3 2020 $45,410,000 $13,252,000 +$4,351,000 +49% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $41,059,000 $12,484,000 -$1,230,000 -9% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $42,289,000 $10,785,000 +$3,911,000 +57% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $38,378,000 $8,889,000 +$3,243,000 +57% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $35,135,000 $8,901,000 +$3,391,000 +62% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $31,744,000 $13,714,000 +$9,004,000 +191% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $22,740,000 $6,874,000 +$3,949,000 +135% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $18,791,000 $5,646,000 +$4,189,000 +288% 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
Q3 2018 $14,602,000 $5,510,000 +$4,382,000 +388% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $10,220,000 $4,710,000 +$3,651,000 +345% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $6,569,000 $2,925,000 +$2,160,000 +282% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $4,409,000 $1,457,000 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $1,128,000 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $1,059,000 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $765,000 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1

Denali Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $102,878,000 -$5,224,000 -4.8% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $108,102,000 +$8,255,000 +8.3% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $99,847,000 +$14,600,000 +17% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $85,247,000 +$34,896,000 +69% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $50,351,000 +$11,973,000 +31% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
2019 $38,378,000 +$19,587,000 +104% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $18,791,000 +$14,382,000 +326% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $4,409,000 +$1,458,000 +49% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $2,951,000 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.